This site is intended for health professionals only
Wednesday 12 December 2018
Share |

Topic: nice

November 8, 2018
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine

Jazz Pharmaceuticals plc has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service (NHS) in England and Wales.
 

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbation.

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

June 26, 2018
The guidance recommends co-prescribing cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease, building on broader prescribing advice from the 2006 guidelines. A spokesperson from NICE said that the change was in response to new trials, including the DOMINO-AD trial in the UK.

The UK’s National Institute for health and Care and Excellence (NICE) has updated dementia guidelines to  include revised prescribing advice, new measures for patients suffering from dementia with lewy bodies (DLB) and a move to primary care treatment.
 

June 6, 2018
Evidence on whether cabozantinib increases the overall length of time people live is “less certain” says the National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) has issued draft guidance rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.

 

Cabometyx (cabozantinib) is a treatment for adult patients with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy.

 

May 17, 2018
NICE U-turn recommends Biogen’s Avonex® (interferon beta-1a) for relapsing-remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has recommended global biotechnology  company Biogen’s Avonex® (interferon beta-1a) as an option for treating relapsing-remitting multiple sclerosis.

 

May 10, 2018
Blood cancer drugs brentuximab, vedotin, midostaurin will now be available on the NHS giving hundreds of individuals more therapy choices

The National Institute for Health and Care Excellence (NICE) has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.

 

Two of the therapies, midostaurin, also known as the Novartis drug Rydapt, and arsenic trioxide, Teva’s Trisenox, are recommended for adults with certain types of leukaemia.

 

May 4, 2018
<p>The NICE decision will result in quicker access for patients to the first selective<br /> IL-23 inhibitor</p>

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending Tremfya® (guselkumab) for treatment of adults with moderate to severe plaque psoriasis.1
 

The NICE recommendation states that guselkumab is recommended as an option for treating plaque psoriasis in adults, only if:

April 11, 2018
After previous negative decision, NICE now recommends Tecentriq® (atezolizumab) for patients whose disease has progressed following standard chemotherapy

The National Institute for Health and Care Excellence (NICE) has recommended new immunotherapy for people with advanced lung cancer.

 

Biotech company Roche has announced that patients with advanced non-small-cell lung cancer (NSCLC) whose disease has progressed following standard chemotherapy, can now access its immunotherapy Tecentriq® (atezolizumab) through the NHS in England and Wales.1

 

March 2, 2018
Welcome news for patients in England, Wales and Northern Ireland as avelumab is recommended for routine NHS use in previously treated metastatic Merkel Cell Carcinoma (mMCC) patients and for use in England within the Cancer Drugs Fund for those with previously untreated mMCC

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) that recommends avelumab for treating adults with metastatic Merkel Cell Carcinoma (mMCC).1

 

February 22, 2018
In 2016, eribulin became the first breast cancer treatment to be recommended by NICE in nearly a decade for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens

Halaven® (eribulin) continues to be available for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens1 even though recent guidance from the National Institute of Health and Care Excellence (NICE) is not recommending eribulin for use in an earlier setting.2

 

February 16, 2018
NICE recommends NHS-wide prescribing of Ipsen’s cabozantinib for patients with medullary thyroid cancer

Ipsen has announced that adult patients in England and Wales with medullary thyroid cancer (MTC) could now benefit from treatment with Cometriq® (cabozantinib).

 

February 15, 2018
Positive NICE recommendation ensures access to Eisai's lenvatinib for subset of patients with very limited options

Eisai Europe Limited has announced that the National Institute for Health and Care Excellence (NICE) issued its final appraisal decision (FAD) recommending reimbursement of Lenvima® (lenvatinib) for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine (RAI-R DTC).1

 

January 19, 2018
Managed access agreement to be developed in parallel to urgently provide effective new treatment to patients in England

The National Institute for Health and Care Excellence (NICE) has formally invited Biogen to submit Spinraza (nusinersen), the first and only disease-modifying treatment for 5q spinal muscular atrophy (SMA), for assessment via the Single Technology Appraisal (STA) route.

 

November 16, 2017
Ribociclib in combination with an aromatase inhibitor is a new and effective treatment option for women in England and Wales with the most common form of advanced breast cancer

Kisqali® (ribociclib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer.

 

November 9, 2017
NICE also recommends use of Merck’s multiple sclerosis therapy cladribine (Mavenclad®) for highly active disease in adults

NHS England has entered into a commercial agreement that allows NHS patients in England immediate access to the innovative new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad®).1

 

NHS England and Merck, the manufacturer of cladribine tablets, have partnered on the commercial access agreement, representing an example of a “win-win-win” for the NHS, patients and industry at a time of intense financial pressure on the NHS.

August 24, 2017
Ribociclib in combination with an aromatase inhibitor is a new and effective treatment option offering postmenopausal women with the most common form of advanced breast cancer the possibility of two years without disease progression

Novartis has announced that Kisqali®(ribociclib) has received authorisation from the European Commission for the treatment of advanced breast cancer. Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.

 

July 20, 2017
Humanised IL-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment

Teva Pharmaceutical Industries Ltd has announced that the National Institute for Health and Care Excellence (NICE) in England has recommended Cinqaero® (reslizumab) in its Final Appraisal Determination (FAD).

July 13, 2017
NICE endorses prescribing across the NHS of Ipsen’s tablet cabozantinib, offering a new therapy option to help battle cancer resistance in advanced renal cell carcinoma in adults (after VEGF-targeted therapy)

The UK affiliate of Ipsen has announced that eligible patients with advanced kidney cancer could now benefit from treatment with Ipsen’s innovative therapy Cabometyx® (cabozantinib) via the NHS in England and Wales, following recommendation for use by NICE in their Final Appraisal Determination (FAD).

May 31, 2017
National Institute for Health and Care Excellence (NICE) recommendation helps fulfil unmet need for rare cancer patients by recommending access to targeted therapy

Novartis has announced that NICE has recommended Afinitor® (everolimus) in its final draft guidance for the treatment of well- or moderately-differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.

 

December 1, 2016
Positive NICE recommendation means patients with severe refractory eosinophilic asthma in England and Wales can now have access to the biologic, mepolizumab

The National Institute for Health and Care Excellence (NICE) has today announced a positive recommendation for GSK’s Nucala®(mepolizumab) for use in a sub-group of adults with severe refractory eosinophilic asthma in England and Wales.1

 

September 30, 2016
Aflibercept will now be the only medicinal product currently approved by the National Institute for Health and Care Excellence as a first-line treatment option for visual impairment due to macular oedema secondary to BRVO

Bayer is pleased to announce that the National Institute for Health and Care Excellence (NICE) has made the final recommendation for aflibercept for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO).1

 

September 2, 2016
NICE has recommended Xofigo® (radium-223 dichloride) in their draft guidance for treating hormone-relapsed prostate cancer with bone metastases to include men in whom docetaxel is contraindicated or not suitable

The National Institute for Health and Care Excellence (NICE) has recommended Xofigo® (radium-223 dichloride) in their draft guidance for adult men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases where docetaxel is contraindicated or is not suitable.1

August 19, 2016
NICE draft guidance does not recommend Nexavar® (sorafenib) for the treatment of patients with advanced hepatocellular carcinoma who have failed or are unsuitable for surgical or loco-regional therapies

The National Institute for Health and Care Excellence (NICE) has released an Appraisal Consultation Document (ACD) with draft guidance not recommending Nexavar® (sorafenib) for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have failed or are unsuitable for surgical or loco-regional therapies.1
 

August 12, 2016
National Institute for Health and Care Excellence publishes negative draft recommendation for brentuximab vedotin within appraisal consultation document

Takeda UK Ltd has announced that brentuximab vedotin (Adcetris®), a medicine that has rapidly become standard of care for patients with relapsed/refractory Hodgkin’s lymphoma (R/R HL),1 has received a negative recommendation within draft guidance from the National Institute for Health and Care Excellence (NICE).2

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine